tbuckley/cabot-search huggingface dataset:
The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
Authors: Antonio Monaco, Veronica Maffia, Nicolina Cristina Sorrentino, Irene Sambri, Yulia Ezhova, Teresa Giuliano, Vincenzo Cacace, Edoardo Nusco, Maria De Risi, Elvira De Leonibus, Thomas Schrader, Frank-Gerrit Klärner, Gal Bitan, Alessandro Fraldi
Journal: Molecular Therapy (2020)

Lysosomal storage diseases (LSDs) are inherited disorders caused by lysosomal deficiencies and characterized by dysfunction of the autophagy-lysosomal pathway (ALP) often associated with neurodegeneration. No cure is currently available to treat neuropathology in LSDs. By studying a mouse model of mucopolysaccharidosis (MPS) type IIIA, one of the most common and severe forms of LSDs, we found that multiple amyloid proteins including α-synuclein, prion protein (PrP), Tau, and amyloid β progressively aggregate in the brain. The amyloid deposits mostly build up in neuronal cell bodies concomitantly with neurodegeneration. Treating MPS-IIIA mice with CLR01, a "molecular tweezer" that acts as a broad-spectrum inhibitor of amyloid protein self-assembly reduced lysosomal enlargement and re-activates autophagy flux. Restoration of the ALP was associated with reduced neuroinflammation and amelioration of memory deficits. Together, these data provide evidence that brain deposition of amyloid proteins plays a gain of neurotoxic function in a severe LSD by affecting the ALP and identify CLR01 as new potent drug candidate for MPS-IIIA and likely for other LSDs.
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
Authors: Kirk R. Schultz, Amina Kariminia, Bernard Ng, Sayeh Abdossamadi, Madeline Lauener, Eneida R. Nemecek, Justin T. Wahlstrom, Carrie L. Kitko, Victor A. Lewis, Tal Schechter, David A. Jacobsohn, Andrew C. Harris, Michael A. Pulsipher, Henrique Bittencourt, Sung Won Choi, Emi H. Caywood, Kimberly A. Kasow, Monica Bhatia, Benjamin R. Oshrine, Allyson Flower, Sonali Chaudhury, Donald Coulter, Joseph H. Chewning, Michael Joyce, Sureyya Savasan, Anna B. Pawlowska, Gail C. Megason, David Mitchell, Alexandra C. Cheerva, Anita Lawitschka, Shima Azadpour, Elena Ostroumov, Peter Subrt, Anat Halevy, Sara Mostafavi, Geoffrey D. E. Cuvelier
Journal: Blood (2020)
Diagnostic Testing for Acute Hepatitis
Authors: Adam E. Mikolajczyk, Nakia L. Chung
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity
Authors: Wei Wu, Doudou Jing, Zibo Meng, Binwu Hu, Binlong Zhong, Xiangyu Deng, Xin Jin, Zengwu Shao
Journal: Theranostics (2020)

Rationale: Mesenchymal cell-derived osteosarcoma is a rare malignant bone tumor affecting children and adolescents. PTEN down-regulation or function-loss mutation is associated with the aggressive of osteosarcoma. Explicating the regulatory mechanism of PTEN might highlight new targets for improving the survival rate of osteosarcoma patients. Methods: The clinical relevance of FGD1 was examined by the TCGA data set, Western blotting and immunohistochemistry of osteosarcoma microarray slides. Functional assays, such as the MTS assay, colony formation assay and xenografts, were used to determine the biological role of FGD1 in osteosarcoma. The protein-protein interaction between FGD1 and PTEN was detected via co-immunoprecipitation. The relationship between FGD1 and PD-L1 was examined by Western blot analysis, RT-qPCR and immunohistochemistry. Results: In this study, analysis of the TCGA data set of sarcomas revealed that FGD1 was over-expressed with the highest P values. Then, we demonstrated that FGD1 was also abnormally up-regulated in osteosarcoma with unfavorable prognosis. Aberrant expressed FGD1 promoted the osteosarcoma tumor cell proliferation and invasion. Moreover, we found that FGD1 was participated in activating PI3K/AKT signaling pathway by interacting with PTEN. Finally, we showed that FGD1 was capable of regulating the tumor immune response via the PTEN/PD-L1 axis in osteosarcoma. Conclusions: Our data suggested that abnormally over-expressed FGD1 functions as an oncogenic protein to promote osteosarcoma progression through inhibiting PTEN activity and activating PI3K/AKT signaling. Notably, FGD1 increased PD-L1 expression in a PTEN dependent manner and modulated the sensitivity of immune checkpoint-based immunotherapy in osteosarcoma. Thus, FGD1 might be a potential target for improving the survival rate of osteosarcomas.
Genetic Mutation in Cytopenic Patients: Distinctive Genomic Profile between Preclinical Vs. Clinical Myelodysplastic Syndrome
Authors: Kritanan Songserm, Amornchai Suksusut, Sunisa Kongkiatkamon, Kitsada Wudhikarn, Chinnachote Teerapakpinyo, Chantiya Chanswangpuwana, Sirorat Kobbuaklee, Shanop Shuangshoti, Udomsak Bunworasate, Ponlapat Rojnuckarin, Chantana Polprasert
Journal: Blood (2019)
A Deep Learning Model for Segmentation of Geographic Atrophy to Study Its Long-Term Natural History
Authors: Bart Liefers, Johanna M. Colijn, Cristina González-Gonzalo, Timo Verzijden, Jie Jin Wang, Nichole Joachim, Paul Mitchell, Carel B. Hoyng, Bram van Ginneken, Caroline C.W. Klaver, Clara I. Sánchez
Journal: Ophthalmology (2020)

Purpose: To develop and validate a deep learning model for automatic segmentation of geographic atrophy (GA) in color fundus images (CFIs) and its application to study growth rate of GA. Participants: 409 CFIs of 238 eyes with GA from the Rotterdam Study (RS) and the Blue Mountain Eye Study (BMES) for model development, and 5,379 CFIs of 625 eyes from the Age-Related Eye Disease Study (AREDS) for analysis of GA growth rate. Methods: A deep learning model based on an ensemble of encoder-decoder architectures was implemented and optimized for the segmentation of GA in CFIs. Four experienced graders delineated GA in CFIs from RS and BMES. These manual delineations were used to evaluate the segmentation model using 5-fold cross-validation. The model was further applied to CFIs from the AREDS to study the growth rate of GA. Linear regression analysis was used to study associations between structural biomarkers at baseline and GA growth rate. A general estimate of the progression of GA area over time was made by combining growth rates of all eyes with GA from the AREDS set. Results: The model obtained an average Dice coefficient of 0.72 $\pm$ 0.26 on the BMES and RS. An intraclass correlation coefficient of 0.83 was reached between the automatically estimated GA area and the graders' consensus measures. Eight automatically calculated structural biomarkers (area, filled area, convex area, convex solidity, eccentricity, roundness, foveal involvement and perimeter) were significantly associated with growth rate. Combining all growth rates indicated that GA area grows quadratically up to an area of around 12 mm$^{2}$, after which growth rate stabilizes or decreases. Conclusion: The presented deep learning model allowed for fully automatic and robust segmentation of GA in CFIs. These segmentations can be used to extract structural characteristics of GA that predict its growth rate.
Neovaginal discharge in transgender women after vaginoplasty: A diagnostic and treatment algorithm
Authors: Wouter B. van der Sluis, Kristin B. de Haseth, Lian Elfering, Müjde Özer, Jan Maerten Smit, Andries E. Budding, Adriaan A. van Bodegraven, Marlon E. Buncamper, Nanne K. H. de Boer, Margriet G. Mullender, Mark-Bram Bouman
Journal: International Journal of Transgender Health (2020)

Surgical construction of a vagina may be indicated in transgender women and cisgender women with congenital or acquired vaginal absence. It has a positive effect on quality of life and generally en...
Abstract P2-08-14: Trends in the incidence of breast cancer following the radiological accident in Goiânia, Brazil: A 25-year analysis
Authors: Marina E Rocha, Rosemar MS Rahal, Ruffo Freitas-Junior, Rosangela S Correa, Danielle CN Rodrigues, Edesio Martins, Leonardo R Soares, Jose C Oliveira
Journal: Cancer Research (2020)

Abstract Background: The largest radiological accident to occur in any urban area happened in a Brazilian state capital city in 1987 to the detriment of the population and the environment. One major concern regarding deleterious effects in the population was a possible increase in breast cancer incidence rates, since the literature shows that exposure of an individual to ionizing radiation is one of the risk factors for cancer. This study analyzed trends in the incidence of breast cancer over the 25-year period following the radiological accident. Methods: This ecological, population-based study was conducted to determine the incidence of breast cancer in female residents of Goiânia, Goiás, Brazil, between 1988 and 2012. The data were collected from the Goiânia population-based cancer registry. Crude and age-standardized incidence rates were calculated. The Joinpoint software program was used to calculate annual percent changes (APC) in the incidence of breast cancer. Results: Overall, 7,365 new cases of breast cancer were identified, with an annual crude incidence rate of 23.09/100,000 women in 1988 and of 71.65/100,000 women in 2012. The age-standardized incidence rate was 35.63/100,000 women in 1988 and 65.63/100,000 women in 2012. Analysis of the APC showed a significant annual increase of 4.8% in the incidence between 1988 and 2005 (p&amp;lt;0.0001) followed by stabilization in 2005-2012, with an APC of -3.5% (p=0.1). Conclusion: There was an increase in the incidence of breast cancer in the female residents of Goiânia, Goiás in the first 17 years of evaluation (1988-2004) followed by a period of stabilization until 2012. Keywords: breast cancer; epidemiology; incidence; age group; Goiânia; Brazil. Table 1. Annual percent change in the age-standardized incidence rate of female breast cancer by age in the city of Goiânia, Goiás, Brazil between 1988 and 2012.Age Group (years)Trend 1 (Years)APC^*(95%CI)pTrend 2 (Years)APC ^*(95%CI)p≤391988-20075.53.9 - 7.20.0012007-2012-7.0-15.3 - 20.140 - 491988-20054.63.6 - 5.60.00012005-2012-3.7-6.5 - -0.80.000150 - 691988-20046.34.6 - 80.00012004-2012-3.4-6.5 - -0.30.0001≥701988-20120.9-0.1 – 1.90.1–---^Significance: p &amp;gt;0.05; * Annual percent change (APC); * Coefficient of the incidence per 100,000 women; CI: Confidence interval. Citation Format: Marina E Rocha, Rosemar MS Rahal, Ruffo Freitas-Junior, Rosangela S Correa, Danielle CN Rodrigues, Edesio Martins, Leonardo R Soares, Jose C Oliveira. Trends in the incidence of breast cancer following the radiological accident in Goiânia, Brazil: A 25-year analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-14.
Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017
Authors: Xurui Jin, Chanchal Chandramouli, Brooke Allocco, Enying Gong, Carolyn S.P. Lam, Lijing L. Yan
Journal: Circulation (2020)

Background: Cardiovascular disease is the leading cause of death among women worldwide, yet, women have historically been underrepresented in cardiovascular trials. Methods: We systematically assessed the participation of women in completed cardiovascular trials registered in ClinicalTrials.gov between 2010 and 2017, and extracted publicly available information including disease type, sponsor type, country, trial size, intervention type, and the demographic characteristics of trial participants. We calculated the female-to-male ratio for each trial and determined the prevalence-adjusted estimates for participation of women by dividing the percentage of women among trial participants by the percentage of women in the disease population (participation prevalence ratio; a ratio of 0.8 to 1.2 suggests comparable prevalence and good representation). Results: We identified 740 completed cardiovascular trials including a total of 862 652 adults, of whom 38.2% were women. The median female-to-male ratio of each trial was 0.51 (25th quartile, 0.32; 75th quartile, 0.90) overall and varied by age group (1.02 in ≤55 year old group versus 0.40 in the 61- to 65-year-old group), type of intervention (0.44 for procedural trials versus 0.78 for lifestyle intervention trials), disease type (0.34 for acute coronary syndrome versus 3.20 for pulmonary hypertension), region (0.45 for Western Pacific versus 0.55 for the Americas), funding/sponsor type (0.14 for government-funded versus 0.73 for multiple sponsors), and trial size (0.56 for smaller [n≤47] versus 0.49 for larger [n≥399] trials). Relative to their prevalence in the disease population, participation prevalence ratio was higher than 0.8 for hypertension, pulmonary arterial hypertension and lower (participation prevalence ratio 0.48 to 0.78) for arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure trials. The most recent time period (2013 to 2017) saw significant increases in participation prevalence ratios for stroke ( P =0.007) and heart failure ( P =0.01) trials compared with previous periods. Conclusions: Among cardiovascular trials in the current decade, men still predominate overall, but the representation of women varies with disease and trial characteristics, and has improved in stroke and heart failure trials.
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia
Authors: Anica M. Wandler, Benjamin J. Huang, Jeffrey W. Craig, Kathryn Hayes, Hannah Yan, Lauren K. Meyer, Alessandro Scacchetti, Gabriela Monsalve, Monique Dail, Qing Li, Jasmine C. Wong, Olga Weinberg, Robert P. Hasserjian, Scott C. Kogan, Philip Jonsson, Keith Yamamoto, Deepak Sampath, Joy Nakitandwe, James R. Downing, Jinghui Zhang, Jon C. Aster, Barry S. Taylor, Kevin Shannon
Journal: Leukemia (2020)
Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group
Authors: Eirini Katodritou, Efstathios Kastritis, Moshe Gatt, Yael C. Cohen, Irit Avivi, Anastasia Pouli, Chrysavgi Lalayianni, Noa Lavi, Sosana Delimpasis, Marie‐Christine Kyrtsonis, Michalis Michael, Celia Suriu, Zektser Miri, Katrin Tzafarti, Chrysanthi Vadikoliou, Dimitris Maltezas, Panagiotis Zikos, Chezi Ganzel, Yuliana Vaxman, Ariel Aviv, Anna Christoforidou, Maria Gavriatopoulou, Adir Shaulov, Evgenia Verrou, Aristea‐Maria Papanota, Gabriel Fakinos, Annita‐Ioanna Gkioka, Vasiliki Palaska, Theodora Triantafyllou, Pavlina Konstantinidou, Achilles Anagnostopoulos, Evangelos Terpos, Meletios A. Dimopoulos
Journal: American Journal of Hematology (2020)

Abstract We investigated incidence, characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) treated mainly with novel therapies. Based on definition (BMPCs &lt;20% and lytic lesions/plasmacytomas, without anemia, renal insufficiency or hypercalcemia) we identified 140 patients with MFMM, among 4650 myeloma patients (3%). Twice the number of patients with typical myeloma were used as controls; 60% were &lt;65 years and 70% had advanced bone disease. Plasmacytomas were more frequent in MFMM compared with standard myeloma (68% vs 15%, P &lt; .05). Adverse prognostic parameters (high lactate dehydrogenase, advanced stage, high risk cytogenetics, immunoparesis) were less common in patients with MFMM compared with controls ( P &lt; .05); 90% received novel agents and 47% underwent autologous transplantation upfront; 90% achieved an objective response; 70% had at least very good partial response which was significantly higher compared with controls ( P &lt; .05). After a median follow‐up of 52 months, 33 patients have died. Early death (&lt;12 months) was infrequent in MFMM. Median progression‐free survival and overall survival (OS) were 46 and 129 months respectively, both significantly longer compared with controls ( P &lt; .001). Proteasome inhibitor (PI)‐based therapy was the only independent predictor for OS in the multivariate analysis (HR: 3.9; P &lt; .001). In conclusion, MFMM is a distinct entity presented in young and elderly subjects, characterized by limited bone marrow infiltration, advanced bone disease and frequent presence of plasmacytomas; MFMM patients have less often adverse prognostic features and achieve excellent responses and prolonged OS especially when treated with PI‐based therapies. Novel imaging will help in a more accurate classification of this entity.
Child health: government must act now to increase investment in services, says BMA
Authors: Abi Rimmer
Journal: BMJ (2020)

A serious lack of investment across a range of child services has left doctors concerned about the adverse impact on child health in England, the BMA has warned. It urged the government to increase investment across the entirety of children’s health and social care services, and reverse local authority cuts in the upcoming budget. A BMA analysis of data1 looking at investment in child services and child health found that:
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics
Authors: Marijke C. C. Langenberg, Marie-Astrid Hoogerwerf, Jan Pieter R. Koopman, Jacqueline J. Janse, Janneke Kos-van Oosterhoud, Carola Feijt, Simon P. Jochems, Claudia J. de Dood, Roos van Schuijlenburg, Arifa Ozir-Fazalalikhan, Mikhael D. Manurung, Erliyani Sartono, Martha T. van der Beek, Béatrice M. F. Winkel, Petra H. Verbeek-Menken, Koen A. Stam, Fijs W. B. van Leeuwen, Pauline Meij, Angela van Diepen, Lisette van Lieshout, Govert J. van Dam, Paul L. A. M. Corstjens, Cornelis H. Hokke, Maria Yazdanbakhsh, Leo G. Visser, Meta Roestenberg
Journal: Nature Medicine (2020)
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
Authors: Sunil K. Joshi, Kristin Qian, William H. Bisson, Kevin Watanabe-Smith, Ariane Huang, Daniel Bottomly, Elie Traer, Jeffrey W. Tyner, Shannon K. McWeeney, Monika A. Davare, Brian J. Druker, Cristina E. Tognon
Journal: Blood (2020)
SOCS proteins: Negative regulators of cytokine signal transduction.
Authors: DJ Hilton, R Starr, D Metcalf, AG Elefanty, M Brysha, TA Willson, EM Viney, NS Sprigg, S Rakar, J Corbin, S Mifsud, L DiRago, NA Nicola, WS Alexander
Journal: Blood (1998)
Reply to Pirus Ghadjar, Thomas Wiegel’s Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732–9
Authors: Elise De Bleser, Piet Ost
Journal: European Urology (2019)
Defining “stable chronic hypercapnia” in patients with COPD: the physiological perspective
Authors: Begum Ergan, Raffaele Scala, Wolfram Windisch
Journal: European Respiratory Journal (2020)

We would like to thank C. Hedsund and co-workers for their commentary on the “European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD” [1]. We agree that the definition of “stable chronic hypercapnia” following exacerbation is challenging. The definition of “stable chronic hypercapnia” following COPD exacerbation is challenging <http://bit.ly/3971r8D>
A biocompatible vascularized graphene oxide (GO)-collagen chamber with osteoinductive and anti-fibrosis effects promotes bone regeneration <i>in vivo</i>
Authors: Huimin Fang, Chao Luo, Shaokai Liu, Muran Zhou, Yuyang Zeng, Jinfei Hou, Lifeng Chen, Shan Mou, Jiaming Sun, Zhenxing Wang
Journal: Theranostics (2020)

The survival of transplanted cells and tissues in bone regeneration requires a microenvironment with a vibrant vascular network. A tissue engineering chamber can provide this in vivo. However, the commonly used silicone chamber is biologically inert and can cause rejection reactions and fibrous capsule. Studies have revealed that collagen is highly biocompatible and graphene oxide (GO) could regulate osteogenic activity in vivo. Besides, GO can be cross-linked with natural biodegradable polymers to construct scaffolds. Methods: A vascularized GO-collagen chamber model was built by placing vessels traversing through the embedded tissue-engineered grafts (osteogenic-induced bone mesenchymal stem cells -gelatin) in the rat groin area. Osteogenic activity and inflammatory reactions were assessed using different methods including micro-CT scanning, Alizarin red staining, and immunohistochemical staining. Results: After one month, in vivo results showed that bone mineralization and inflammatory responses were significantly pronounced in the silicone model or no chamber (control) groups. Vascular perfusion analysis confirmed that the GO-collagen chamber improved the angiogenic processes. Cells labeled with EdU revealed that the GO-collagen chamber promoted the survival and osteogenic differentiation of bone mesenchymal stem cells. Conclusion: Overall, the novel biocompatible GO-collagen chamber exhibited osteoinductive and anti-fibrosis effects which improved bone regeneration in vivo. It can, therefore, be applied to other fields of regenerative medicine.
Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer
Authors: Fa-Chyi Lee
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Genetic Vulnerabilities of DNMT3AR882H in Myeloid Malignancies
Authors: Malgorzata Gozdecka, Monika Dudek, Konstantinos Tzelepis, Aristi Damaskou, Vijay Baskar, Penny Wright, Graham Duddy, Eshwar Meduri, Milena Mazan, Kosuke Yusa, Brian J. P. Huntly, George S. Vassiliou
Journal: Blood (2019)